Related Experiment Video
Updated: May 10, 2026
06:01
A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia
Published on: August 18, 2015
AGT M235T polymorphisms and ischemic stroke risk: a meta-analysis.
Baoyun Liang1, Lilan Qin, Huijun Wei
1Department of Internal Neurology, First Affiliated Hospital of Guangxi University of Chinese Medicine, Nanning, Guangxi, China.
Journal of the Neurological Sciences
|June 25, 2013
Summary
This meta-analysis found the AGT M235T polymorphism is a risk factor for ischemic stroke (IS) in Asians. However, this association was not observed in Caucasians, suggesting ethnic differences in IS genetic risk factors.
Area of Science:
- Genetics
- Epidemiology
- Cardiovascular Disease
Background:
- The angiotensinogen (AGT) M235T polymorphism has been investigated for its association with ischemic stroke (IS).
- Previous studies yielded inconsistent results regarding this association.
- A comprehensive meta-analysis is needed to clarify the relationship between AGT M235T polymorphism and IS risk.
Purpose of the Study:
- To conduct a meta-analysis evaluating the association between the AGT M235T polymorphism and ischemic stroke (IS).
- To assess potential ethnic differences in the association between AGT M235T polymorphism and IS.
- To explore the overall risk conferred by the AGT M235T polymorphism across different genetic models.
Main Methods:
- Systematic literature search of multiple databases (PubMed, EMBASE, CNKI, CBM, Wanfang, Chongqing VIP) up to January 2013.
- Meta-analysis using STATA software, calculating Odds Ratios (OR) with 95% Confidence Intervals (CI).
- Assessment of heterogeneity (Q-test, I² statistic) and publication bias (funnel plots, Egger's regression test). Cumulative meta-analysis was performed.
Main Results:
- A significant association between AGT M235T polymorphism and IS was found across multiple genetic models (dominant, recessive, over-dominant, co-dominant, allele).
- Subgroup analyses revealed significant associations in Asian populations and with hospital-based controls.
- Cumulative analysis indicated a tendency towards a significant association over time, but an opposite trend was observed in Caucasians.
Conclusions:
- The AGT M235T polymorphism may serve as a risk factor for ischemic stroke (IS) in Asian populations.
- The association between AGT M235T polymorphism and IS appears to be ethnicity-dependent, with no significant link found in Caucasians.
- Further research is warranted to validate these findings and elucidate the ethnic-specific role of AGT M235T polymorphism in IS pathogenesis.
Related Concept Videos
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:15Ischemic Stroke l: Introduction
Ischemic stroke is an acute cerebrovascular condition in which blood flow to a brain region is suddenly interrupted, leading to tissue infarction. Neurons depend on continuous oxygen and glucose supply, so even brief reductions in perfusion cause energy failure, ionic imbalance, and irreversible injury. Ischemic strokes are classified into thrombotic and embolic types based on their underlying mechanisms.Thrombotic MechanismsThrombotic stroke develops when a clot forms within a cerebral artery.
01:15Ischemic Stroke ll: Pathophysiology
An ischemic stroke occurs when a cerebral blood vessel becomes obstructed, most often by a thrombus or embolus, interrupting the delivery of oxygen and glucose to brain tissue. Because neurons rely on continuous aerobic metabolism, energy failure begins within minutes of reduced perfusion. The region receiving the least blood flow becomes the infarct core, an area of irreversible cellular death. Surrounding this core lies the penumbra, a zone of hypoperfused but still viable tissue that is...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:17Ischemic Heart Disease: Overview
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and narrowing...
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and narrowing...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...